The tweet was deleted by the author.
But we saved everything 🙂.
Two of the pharmaceutical industry's leading executives, Pascal Soriot of AstraZeneca and Rob Davis of Merck, have underscored their companies' ongoing strategic partnerships with Tempus. The collaborations focus on leveraging artificial intelligence in the field of oncology.
Eric Lefkofsky's commentary follows the announcement of these partnerships, which aim to accelerate the integration of AI solutions for cancer diagnostics and therapies. The involvement of major pharmaceutical firms signals continued investment in digital health innovation.
Eric Lefkofsky previously introduced Preview, an AI platform that delivers pathology insights to doctors within 24 hours, aiming to speed up clinical decision-making for patient care.
Tempus recently secured U.S. FDA approval for its xT CDx platform, expanding tumor-only genomic profiling access to more patients. Both developments highlight Tempus's ongoing push to integrate advanced technology into oncology.